ストックスクリーナーアプリを入手
2.965
5.27%
-0.165
アフターアワーズ：
2.97
0.005
+0.17%
Prime Medicine Inc (PRME) 最新ニュース
Comparing Qiagen (NYSE:QGEN) & Prime Medicine (NYSE:PRME) - Defense World
Sumitomo Mitsui Trust Group Inc. Has $9.02 Million Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine (NYSE:PRME) Raised to Sell at StockNews.com - Defense World
Analysts review Prime Medicine Inc’s rating - Knox Daily
Closing Figures: Prime Medicine Inc (PRME)’s Negative Finish at 2.47, Down -1.98 - The Dwinnex
There is no way Prime Medicine Inc (PRME) can keep these numbers up - SETE News
Prime Medicine: Gene Editing Company, Risky Investment (NASDAQ:PRME) - Seeking Alpha
Metric Analysis: Prime Medicine Inc (PRME)’s Key Ratios in the Limelight - The Dwinnex
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.13 - MarketBeat
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) PT at $13.13 - Defense World
Nisa Investment Advisors LLC Buys 12,507 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Layoff Tracker: Thermo Fisher to Cut 300 People Across 2 Massachusetts Sites - BioSpace
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm -January 30, 2025 at 12:27 pm EST - Marketscreener.com
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PR Newswire
PBM Prime Therapeutics to Pay $10 Million Antitrust Case Over Price-Fixing Scheme with Express Scripts, Inc. - Policy & Medicine
Barclays PLC Increases Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to Sell - MarketBeat
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to “Sell” - Defense World
Alliance for Regenerative Medicine: Field growing, cost still an issue - BioWorld Online
Prime Medicine Advances Gene Editing and Trials - TipRanks
Jane Street Group LLC Trims Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Average Price Target from Analysts - Defense World
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Prime Medicine (NYSE:PRME) Rating Increased to Sell at StockNews.com - Defense World
Prime Medicine (NYSE:PRME) Upgraded at StockNews.com - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $5.26 Million Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Barclays PLC Boosts Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
State Street Corp Buys 43,086 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Prime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.com - MarketBeat
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal 2025 - Investing.com
When Would Be The Best Time To Buy Prime Medicine Inc (NASDAQ: PRME) Stock? - Stocks Register
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Consensus Price Target from Analysts - Defense World
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):